Turkish Abstract Abstract PDF Similar Articles Mail to Author

¹Uludağ Üniversitesi Tıp Fakültesi, Göz Hastalıkları A.D., Bursa, Doç. Dr.
²Uludağ Üniversitesi Tıp Fakültesi, Göz Hastalıkları A.D., Bursa, Uz. Dr.
³Uludağ Üniversitesi Tıp Fakültesi, Göz Hastalıkları A.D., Bursa, Asist. Dr.
⁴Uludağ Üniversitesi Tıp Fakültesi, Göz Hastalıkları A.D., Bursa, Prof. Dr. Purpose: To assess the impact of intravitreal bevacizumab (IVB) on the following surgical complications and early results of trabeculectomy with mitomycin-C in neovascular glaucoma (NVG).
Materials and Methods: Cases with the diagnosis of NVG and intraocular pressures >40 mmHg, visual acuities between hand-motion and 0,1 and prominent corneal edema were included in this study. Primarily, IOPs were assessed at the third day of intravitreal injections. Subsequently fornix based MMC trabs were performed 7 to 10 days after injections. Along with anterior segment photography, follow-up examinations were done on the first postoperative week and on the first month.
Results: Ten eyes of 10 cases, between the age of 44 and 67 years (mean of 57.0±10), were included in this study. Five of the cases were male and the other five were female. Mean IOP reading was 35±4.5 mmHg (29-38 mmHg) on the third day of IVB injection. IOP were 12±3.2 mmHg (10-17 mmHg) and 15±3.2 mmHg (10-18 mmHg) respectively on the first postoperative week and on the first month. In all eyes, corneal edema regressed significantly and a diffuse filtering bleb was present.
Discussion: In eyes with NVG, bevacizumab enables to perform an easier surgery and helps to maintain a better control of IOP postoperatively when it is injected intravitreally before MMC trab. In this way, an extra time can be saved for additional interventions that would treat the specific underlying condition that results with NVG. Keywords : Neovascular glaucoma, intravitreal injection